Early Stage Partners
Venture capital firm founded in 2001 focused on investing in early-stage technology companies in the U.S. Midwest. ESP provides capital, advice and connections to support company growth and to generate returns for limited partners. The firm launched ESP Fund I (2002) and ESP Fund II (2008) and cites multiple exits, including a combined ~ $750M of portfolio exits in 2014.
Industries
Nr. of Employees
small (1-50)
Early Stage Partners
Portfolio
Announced a joint development agreement with Archer Daniels Midland Company to develop and commercialize cavitation technology (April 26, 2017).
#Industrial / agricultural processing technology (hydrodynamic cavitation)
Developed TempTraq, a disposable Bluetooth wearable continuous temperature patch; study at Cleveland Clinic showed agreement with pulmonary artery catheter measurements; TempTraq integrated with TempTraq Connect (HIPAA-compliant) and used by University Hospitals during COVID-19 (April 20, 2020); system FDA, CE and TGA cleared (per site content).
#Wearable medical device / digital health (TempTraq continuous temperature monitor)
Developing Edison RAST platform (Robotically Assisted Sonic Therapy). ESP participated in financings including Series B (first close $8.3M, 2017). Company raised a $54M Series C in 2019 (reported on ESP site); received Frost & Sullivan 2019 North American Technology Innovation Award; recognized by The Observer among top healthcare startups.
#Medical device / therapeutic technology (histotripsy, non-invasive tumor ablation)
#Unknown (name only listed on ESP portfolio page)
ESP participated in multiple financing rounds. OnShift closed an $18M Series D on April 13, 2016 (Health Velocity Capital led; ESP participated). In October 2018 OnShift received a strategic equity investment led by Clearlake Capital with participation from earlier investors including ESP. OnShift reports thousands of customers (~5,000 referenced in a 2018 press release).
#Software / healthcare IT (human capital management for post-acute care and senior living)
#Materials / polymers (name listed on portfolio page)
Announced a joint development agreement with Archer Daniels Midland Company to develop and commercialize cavitation technology (April 26, 2017).
#Industrial / agricultural processing technology (hydrodynamic cavitation)
Developed TempTraq, a disposable Bluetooth wearable continuous temperature patch; study at Cleveland Clinic showed agreement with pulmonary artery catheter measurements; TempTraq integrated with TempTraq Connect (HIPAA-compliant) and used by University Hospitals during COVID-19 (April 20, 2020); system FDA, CE and TGA cleared (per site content).
#Wearable medical device / digital health (TempTraq continuous temperature monitor)
Developing Edison RAST platform (Robotically Assisted Sonic Therapy). ESP participated in financings including Series B (first close $8.3M, 2017). Company raised a $54M Series C in 2019 (reported on ESP site); received Frost & Sullivan 2019 North American Technology Innovation Award; recognized by The Observer among top healthcare startups.
#Medical device / therapeutic technology (histotripsy, non-invasive tumor ablation)
#Unknown (name only listed on ESP portfolio page)
ESP participated in multiple financing rounds. OnShift closed an $18M Series D on April 13, 2016 (Health Velocity Capital led; ESP participated). In October 2018 OnShift received a strategic equity investment led by Clearlake Capital with participation from earlier investors including ESP. OnShift reports thousands of customers (~5,000 referenced in a 2018 press release).
#Software / healthcare IT (human capital management for post-acute care and senior living)
#Materials / polymers (name listed on portfolio page)